File Download

There are no files associated with this item.

Supplementary

Conference Paper: GOFURTGO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)

TitleGOFURTGO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)
Authors
Yau, TCC
Issue Date2010
Citation
Asian Oncology Summit (AOS) 2010, Bali, Indonesia, 9-11 April 2010 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/254287

 

DC FieldValueLanguage
dc.contributor.authorYau, TCC-
dc.date.accessioned2018-06-13T02:01:54Z-
dc.date.available2018-06-13T02:01:54Z-
dc.date.issued2010-
dc.identifier.citationAsian Oncology Summit (AOS) 2010, Bali, Indonesia, 9-11 April 2010-
dc.identifier.urihttp://hdl.handle.net/10722/254287-
dc.languageeng-
dc.relation.ispartofAsian Oncology Summit,2010-
dc.titleGOFURTGO trial (GFG) – an AGITG multicentre phase II study of fixed dose rate gemcitabine-oxaliplatin (Gem-Ox) integrated with concomitant 5FU and 3-D conformal radiotherapy (5FU-3DRT) for the treatment of locally advanced pancreatic cancer (LAPC)-
dc.typeConference_Paper-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.hkuros216986-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats